Takeda launches CINRYZE in India for hereditary angioedema patients
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Ayúdame3D has become a leading social entity in social technology.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
This partnership stemmed from a successful customer-supplier relationship spanning several years.
The investment will enable the company to enter European markets as well as enhance margins in current markets
Subscribe To Our Newsletter & Stay Updated